Tiziana Life Sciences PLC’s Stock Is Sell After Today’s Huge Decline

 Tiziana Life Sciences PLC's Stock Is Sell After Today's Huge Decline

The stock of Tiziana Life Sciences PLC (LON:TILS) is a huge mover today! The stock decreased 5.79% or GBX 12.3 on November 18, hitting GBX 200.2. About 12,492 shares traded hands or 262.51% up from the average. Tiziana Life Sciences PLC (LON:TILS) has risen 41.20% since April 20, 2016 and is uptrending. It has outperformed by 36.77% the S&P500.
The move comes after 7 months negative chart setup for the GBX 228.98 million company. It was reported on Nov, 18 by Barchart.com. We have GBX 172.17 PT which if reached, will make LON:TILS worth GBX 32.06 million less.

More notable recent Tiziana Life Sciences PLC (LON:TILS) news were published by: Marketwired.com which released: “Tiziana Life Sciences PLC: Appointment of Dr. Robert Evans” on May 04, 2016, also Marketwired.com with their article: “Tiziana Life Sciences plc Tiziano Lazzaretti Appointed as Chief Financial Officer” published on April 04, 2016, Marketwired.com published: “Tiziana Life Sciences PLC Announces Interim Results for the Six Months Ended …” on September 29, 2016. More interesting news about Tiziana Life Sciences PLC (LON:TILS) were released by: Businesswire.com and their article: “Tiziana Life Sciences Announces New Data with Foralumab, a Fully Human Anti …” published on November 16, 2016 as well as Bloomberg.com‘s news article titled: “Tiziana Life Sciences to Raise $3.3 Million in London IPO” with publication date: March 30, 2014.

Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The company has a market cap of 228.98 million GBP. The Firm is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. It currently has negative earnings. The Company’s products in clinical stage include Milciclib and Foralumab.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment